At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 287 enrolled
Drug / intervention
Reparixin +1 moredrug
Likely dose
Reparixin 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia
In Brief
A Phase 3 clinical trial evaluating Reparixin and Placebo for Pneumonia, Viral. Completed, enrolled 287 participants across 17 sites in 2 countries.
Detailed Summary
The study objective is to assess Efficacy and safety of Reparixin treatment as compared to placebo (both on top of standard treatment) in adult patients with severe COVID-19 pneumonia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPneumonia, Viral
CountriesItaly, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
Enrollment StartFeb 2021
First PostedMay 2021
Primary CompletionSep 2021
Study CompletionOct 2021
TodayJul 2026
First PostedMay 7, 2021
Enrollment StartFeb 14, 2021
Primary CompletionSep 30, 2021
Study CompletionOct 31, 2021
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 5.2 years ago
Interventions
Reparixindrug
2 tablets of Reparixin (600 mg each), for the total of three daily administrations (6 tablets daily).
Placeboother
Matched placebo, i.e. 2 tablets for the total of three daily administrations (6 tablets daily).